Review articleLeishmania treatment and prevention: Natural and synthesized drugs
-
Add time:09/06/2019 Source:sciencedirect.com
Leishmaniasis affects over 150 million people all over the world, especially in subtropical regions. Currently used antileishmanial synthesized drugs are associated with some drawbacks such as resistance and cytotoxicity, which hamper the chances of treatment. Furthermore, effective leishmanial vaccines are not well developed. Promising chemotherapy, either from natural or synthetic compounds, was or still is the most promising treatment. This review focuses on recent findings in drugs used for the treatment of leishmaniasis including; chemical and natural antileishmanial moieties, different potential targets, as well as various trials of vaccination development. Special emphasis has been paid to the mechanisms of the drugs, their safety and where possible, the structure-activity relationship to enable guided future drug discovery.
We also recommend Trading Suppliers and Manufacturers of Leishmania peptide 183 (cas 138655-13-7). Pls Click Website Link as below: cas 138655-13-7 suppliers
Prev:Review articleTinkering with targeting nucleotide signaling for control of intracellular Leishmania parasites
Next:Invited ReviewProtein turnover and differentiation in Leishmania) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis09/26/2019
- Report2.8-Å Cryo-EM Structure of the Large Ribosomal Subunit from the Eukaryotic Parasite Leishmania09/25/2019
- Research PaperA single-cysteine mutant and chimeras of essential Leishmania Erv can complement the loss of Erv1 but not of Mia40 in yeast09/24/2019
- Review article1988–2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research09/10/2019
- Identification of proteins interacting with HSP70 mRNAs in Leishmania braziliensis☆09/09/2019
- Research paperA recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection09/08/2019
- Invited ReviewProtein turnover and differentiation in Leishmania09/07/2019
- Review articleTinkering with targeting nucleotide signaling for control of intracellular Leishmania parasites09/05/2019
- Bioinformatics analysis of four proteins of Leishmania donovani to guide epitopes vaccine design and drug targets selection09/04/2019
